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Abstract		
	
Background:	The	T	 cell	 bispecific	 antibody	 cibisatamab	 (CEA-TCB)	binds	Carcino-Embryonic	
Antigen	 (CEA)	on	cancer	cells	and	CD3	on	T	cells,	which	triggers	T	cell	killing	of	 cancer	cell	
lines	expressing	moderate	to	high	levels	of	CEA	at	the	cell	surface.	Patient	derived	colorectal	
cancer	 organoids	 (PDOs)	may	more	 accurately	 represent	 patient	 tumors	 than	 established	
cell	 lines	which	potentially	enables	more	detailed	 insights	 into	mechanisms	of	cibisatamab	
resistance	and	sensitivity.	
	
Methods:	We	established	PDOs	from	multidrug-resistant	metastatic	CRCs.	CEA	expression	of	
PDOs	was	determined	by	FACS	and	sensitivity	to	cibisatamab	immunotherapy	was	assessed	
by	co-culture	of	PDOs	and	allogeneic	CD8	T	cells.	
	
Results:	 PDOs	 could	 be	 categorized	 into	 3	 groups	 based	 on	 CEA	 cell-surface	 expression:	
CEAhi	(n=3),	 CEAlo	(n=1)	 and	 CEAmixed	 PDOs	 (n=4),	 that	 stably	 maintained	 populations	 of	
CEAhi	and	CEAlo	cells,	which	has	not	previously	been	described	 in	CRC	cell	 lines.	CEAhi	PDOs	
were	 sensitive	 whereas	 CEAlo	 PDOs	 showed	 resistance	 to	 cibisatamab.	 PDOs	 with	 mixed	
expression	showed	low	sensitivity	to	cibisatamab,	suggesting	that	CEAlo	cells	maintain	cancer	
cell	 growth.		 Culture	 of	 FACS-sorted	 CEAhi	and	 CEAlo	 cells	 from	 PDOs	 with	 mixed	 CEA	
expression	 demonstrated	 high	 plasticity	 of	 CEA	 expression,	 contributing	 to	 resistance	
acquisition	 through	 CEA	 antigen	 loss.	 RNA-sequencing	 revealed	 increased	WNT/β-catenin	
pathway	activity	in	CEAlo	cells.	Cell	surface	CEA	expression	was	up-regulated	by	inhibitors	of	
the	WNT/β-catenin	pathway.	
	
Conclusions:	 Based	 on	 these	 preclinical	 findings,	 heterogeneity	 and	 plasticity	 of	 CEA	
expression	appear	to	confer	 low	cibisatamab	sensitivity	 in	PDOs,	supporting	further	clinical	
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evaluation	 of	 their	 predictive	 effect	 in	 CRC.		 Pharmacological	 inhibition	 of	 the	 WNT/β-
catenin	pathway	may	be	a	rational	combination	to	sensitize	CRCs	to	cibisatamab.	Our	novel	
PDO	and	T	cell	co-culture	immunotherapy	models	enable	pre-clinical	discovery	of	candidate	
biomarkers	and	combination	therapies	that	may	inform	and	accelerate	the	development	of	
immuno-oncology	agents	in	the	clinic.	
	
Keywords:	cibisatamab,	CEA,	immunotherapy,	patient-derived	organoids,	WNT/β-catenin	
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Background	
Colorectal	cancer	(CRC)	is	the	third	most	common	cause	of	cancer	related	mortality	
worldwide(1).	Median	overall	survival	for	patients	with	metastatic	CRC	has	increased	to	over	
24	months	since	the	introduction	of	anti-vascular	endothelial	growth	factor	(VEGF)	and	anti-
epidermal	growth	factor	(EGFR)	targeted	therapies(2).	Trifluridine-tipiracil	(TAS102)	and	the	
multi-kinase	inhibitor	regorafenib	are	recently	developed	third	line	therapy	options	but	their	
survival	 benefit	 is	 only	modest(3),(4).	 Thus,	 new	 therapies	 are	 needed	 to	 further	 improve	
outcomes	of	patients	with	metastatic	CRC.	
Checkpoint-inhibiting	 immunotherapies	 recently	 led	 to	 substantial	 increase	 in	
survival	 in	 some	 tumor	 types.	 These	 include	 hypermutated	 microsatellite	 instable	 (MSI)	
CRCs(5),(6)	but	checkpoint	inhibitors	showed	no	activity	in	microsatellite	stable	(MSS)	CRCs.	
High	 numbers	 of	 mutation	 encoded	 neo-antigens	 in	 MSI	 CRCs	 are	 thought	 to	 foster	
spontaneous		immune		response		with	increased	cytotoxic	CD8	T	cell	infiltrates	that	are	kept	
in	 check	 by	 cancer	 cells	 through	 upregulation	 of	 PD-L1(7).	 Unfortunately,	 only	 ~5%	 of	
metastatic	 CRCs	 display	 the	MSI	 phenotype(8).	 Thus,	 benefit	 from	 checkpoint	 inhibitors	 is	
currently	restricted	to	a	small	subgroup	of	CRC	patients(9).	
The	T	cell	bispecific	antibody	cibisatamab	(CEA-TCB)	is	a	novel	immunotherapy	that	
redirects	T	 cells	 independently	of	 their	T	 cell	 receptor	 specificity	 to	 tumor	 cells	expressing	
the	carcinoembryonic	antigen	(CEA)	glycoprotein	at	the	cell	surface(10).	A	major	advantage	
of	 T	 cell	 redirecting	 bispecific	 antibodies	 is	 that	 they	mediate	 cancer	 cell	 recognition	 by	 T	
cells	 independently	 of	 neoantigen	 load.	 CEA	 is	 overexpressed	 on	 the	 cell	 surface	 of	many	
colorectal	 cancers	 and	 cibisatamab	 is	 hence	 a	 promising	 immunotherapy	 agent	 for	 non	
hypermutated	MSS	CRCs.		
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Cibisatamab	has	a	 single	binding	 site	 for	 the	CD3	epsilon	 chain	on	T	 cells	 and	 two	
CEA	binding	sites	which	tune	the	binding	avidity	to	cancer	cells	with	moderate	to	high	CEA	
cell	 surface	 expression(11).	 This	 avoids	 targeting	 of	 healthy	 epithelial	 cells	 with	 low	 CEA	
expression	levels,	which	are	physiologically	present	in	some	tissues.	Binding	of	cibisatamab	
to	CEA	on	the	surface	of	cancer	cells	and	of	CD3	on	T	cells	triggers	T	cell	activation,	cytokine	
secretion	and	cytotoxic	granule	release.	The	phase	I	trial	of	cibisatamab	in	patients	with	CEA	
expressing	 metastatic	 CRCs	 that	 had	 failed	 at	 least	 two	 prior	 chemotherapy	 regimens	
showed	 antitumor	 activity	 with	 radiological	 shrinkage	 in	 11%	 (4/36)	 and	 50%	 (5/10)	 of	
patients	 treated	 with	 monotherapy	 or	 in	 combination	 with	 PD-L1-inhibiting	 antibodies,	
respectively(12),(13).	 Based	 on	 these	 results,	 CEA	 is	 one	 of	 the	 most	 promising	 target	
antigens	 for	 immunotherapy	 in	MSS	CRCs.	 Although	 some	patients	 in	 this	 dose	 escalation	
trial	 were	 treated	 with	 a	 dose	 below	 the	 final	 recommended	 dose,	 the	 response	 rates	
nevertheless	indicate	that	a	subgroup	of	tumors	is	resistant	to	treatment.		
Molecular	 mechanisms	 of	 cibisatamab	 activity	 have	 been	 investigated	 in	 CRC	 cell	
lines	in	vitro	using	killing	assays	with	peripheral	blood	mononuclear	cells(11).	This	identified	
CEA	expression	as	a	major	determinant	of	cibisatamab	sensitivity	as	only	cell	lines	expressing	
moderate	 to	 high	 CEA	 levels	 were	 susceptible	 to	 T	 cell	 mediated	 killing.	 In	 contrast,	
cibisatamab	sensitivity	was	 independent	of	 the	presence	of	mutations	 in	CRC	driver	genes	
such	as	APC,	TP53,	KRAS	and	BRAF.		
Recently	 developed	 protocols	 allow	 the	 expansion	 and	 long	 term	 propagation	 of	
cancer	cells	as	so	called	patient	derived	organoids	(PDOs)	from	CRC	biopsies(14).	PDOs	have	
been	 suggested	 to	 better	 represent	 the	 biological	 characteristics	 of	 patient	 tumors	 than	
cancer	 cell	 lines	which	were	 often	 established	 decades	 ago	 and	 have	 undergone	 changes	
during	 long	 term	 culture	 on	 plastic.	 The	 ability	 to	 rapidly	 generate	 model	 systems	 from	
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patients	furthermore	enables	matching	of	disease	stage	and	prior	treatment	history	to	those	
of	patients	in	whom	novel	drugs	are	clinically	tested.	
Identification	 of	 resistance	 mechanisms	 for	 novel	 immunotherapies	 in	 patient-
relevant	 preclinical	 models	 should	 define	 candidate	 biomarkers	 for	 the	 identification	 of	
sensitive	 patient	 subgroups	or	 of	 combination	 therapy	 strategies	 that	 enhance	 efficacy	 by	
co-targeting	of	resistance	pathways.	This	could	maximize	trial	success	rate	and	prevent	drug	
attrition,	which	 remains	 common	 for	new	cancer	drugs	 in	 the	absence	of	biomarkers.	 The	
aim	 of	 this	 study	 was	 to	 investigate	 mechanisms	 of	 resistance	 to	 cibisatamab	
immunotherapy	beyond	 those	 identified	 in	cell	 lines	by	using	PDO	models	 from	treatment	
refractory	 metastatic	 CRCs.	 To	 this	 end,	 we	 established	 seven	 PDOs	 from	 chemotherapy	
resistant	metastatic	CRCs	and	one	from	a	treatment	naïve	primary	CRC	and	developed	an	in	
vitro	co-culture	assay	with	CD8	T	cells	to	assess	cibisatamab	efficacy.		
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Material	and	methods	
Human	samples	and	cell	lines	
Imaging-guided	 core	 biopsies	 from	 metastatic	 colorectal	 cancers	 that	 had	 been	
treated	with	 at	 least	 two	prior	 lines	of	 chemotherapy	were	obtained	 from	 the	Prospect	 C	
and	 Prospect	 R	 trials	 (Chief	 investigator:	 D.	 Cunningham,	 UK	 national	 ethics	 committee	
approval	numbers:	12/LO/0914	and	14/LO/1812,	respectively).	One	endoscopic	biopsy	from	
a	 treatment	 naïve	 primary	 colorectal	 cancer	 was	 obtained	 from	 the	 FOrMAT	 trial	 (Chief	
investigator:	N.	Starling,	UK	national	ethics	committee	approval	number	13/LO/1274).	Trials	
were	run	at	the	Royal	Marsden	Hospital	and	all	patients	provided	written	informed	consent	
before	trial	inclusion.	Anonymized	buffy	coats	from	healthy	donors	were	obtained	from	the	
local	 blood	 bank	 (National	 ethics	 committee	 approval	 number	 06/Q1206/106) or	 through	
the	Improving	Outcomes	 in	Cancer	biobanking	protocol	at	the	Barts	Cancer	Institute	(Chief	
investigator:	T.	Powles,	UK	national	ethics	committee	approval	number:	13/EM/0327)	from	
individuals	providing	written	informed	consent.	DLD-1	and	MKN-45	cell	lines	were	obtained	
from	 the	 American	 Type	 Culture	 Collection	 and	 were	 maintained	 in	 RPMI	 1640	 medium	
supplemented	with	10%	FBS,	1X	Glutamax	and	100units/ml	penicillin/streptomicin	(Thermo	
Fisher). 
Generation	of	patient	derived	organoids		
PDO	cultures	from	CRC-01,	CRC-02	and	CRC-06	were	established	directly	from	core	
biopsies	 by	 rough	 chopping	 followed	 by	 embedding	 in	 growth	 factor	 reduced	 Matrigel	
(Corning).	Very	small	biopsy	fragments	were	available	from	CRC-03,	CRC-04,	CRC-05,	CRC-07	
and	 CRC-08	 and	 these	 were	 first	 grafted	 subcutaneously	 or	 under	 the	 kidney	 capsule	 of	
female	 CD1	 nude	 mice	 by	 the	 Tumour	 Profiling	 Unit	 at	 the	 Institute	 of	 Cancer	 Research	
(Home	 office	 licence	 number	 PD498FF8D).	Mice	were	 culled	 once	 tumors	 had	 grown	 and	
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tumors	were	 removed	 and	 dissociated	 in	 a	 gentleMAX	Octo	 dissociator	 using	 the	 Human	
Tumour	Dissociation	Kit	(Miltenyi	Biotec).	Mouse	cells	were	magnetically	removed	using	the	
Mouse	Cell	Depletion	Kit	(Miltenyi	Biotec),	and	purified	human	tumour	cells	were	embedded	
into	 growth	 factor	 reduced	 Matrigel.	 PDOs	 were	 expanded	 in	 Matrigel	 as	 described(14)	
using	 Advanced	 DMEM/F12	 media	 supplemented	 with	 1X	 Glutamax,	 100	 units/ml	
penicillin/streptomycin,	 1X	 B27,	 1X	 N2,	 10mM	 HEPES	 (all	 Thermo	 Fisher),	 1mM	 N-acetyl	
cysteine,	 10mM	 nicotinamide,	 10uM	 SB202190,	 10nM	 gastrin,	 10uM	 Y27632	 (Sigma	
Aldrich),	 10nM	 prostaglandin	 E2,	 500nM	 A-83-01,	 100ng/ml	 Wnt3a	 (Biotechne),	 50ng/ml	
EGF	 (Merck),	1ug/ml	R-Spondin,	100ng/ml	Noggin,	and	100ng/ml	FGF10	 (Peprotech).	After	
at	least	2	months	of	continuous	growth	in	the	matrigel	matrix	(minimum	of	12	passages),	the	
PDOs	were	 first	eGFP	 tagged	 (see	below)	and	 then	adapted	 to	grow	 in	DMEM/F12	 (Sigma	
Aldrich)	 with	 20%	 fetal	 bovine	 serum	 (FBS),	 1X	 Glutamax,	 100	 units/ml	
penicillin/streptomycin	 containing	 2%	 Matrigel.	 PDO	 cultures	 were	 maintained	 in	 these	
conditions	 and	 used	 as	 required	 for	 T	 cell	 co-culture	 assays	 and	 FACS	 analysis.	 Genetic	
analyses	 of	 colon	 cancer	 driver	 genes	were	 performed	 on	 each	 PDO	 line	 and	 these	were	
identical	to	the	mutations	that	had	been	identified	in	the	matched	tumor	biopsies.		
Labelling	of	PDOs	with	nuclear	eGFP	
The	 nuclei	 of	 PDOs	 were	 labelled	 by	 introducing	 an	 eGFP	 tagged	 histone	 2B	
construct	 (pLKO.1-LV-H2B-GFP)(15)	 to	enable	cell	quantification	by	automated	microscopy.	
For	 virus	 generation,	HEK-293T	 cells	were	 cultured	 in	DMEM	 supplemented	with	 10%FBS,	
1XGlutamax	and	100units/ml	penicillin/streptomycin.	Lentiviral	particles	were	produced	by	
overnight	 transfection	with	a	plasmid	mixture	containing	9	μg	of	pLKO.1-LV-H2B-GFP,	2.25	
μg	 of	 psPAX2	 packaging	 plasmid	 (gift	 from	 Didier	 Trono;	 Addgene	 plasmid	 #12260;	
http://n2t.net/addgene:12260	 ;	 RRID:Addgene_12260)	 and	 0.75	 ug	 of	 pMD2.G	 envelope	
plasmid		(gift	from	Didier	Trono;	Addgene	plasmid	#	12259;	http://n2t.net/addgene:12259;	
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RRID:Addgene_12259)	using		TransIT-293	transfection	reagent	(Mirus).	The	cells	were	media	
changed	 the	 following	 day,	 virus	 harvested	 after	 24	 hours	 and	 passed	 through	 a	 0.45uM	
filter	 before	 use.	 For	 lentiviral	 transduction	 PDOs	 were	 harvested	 from	 the	 cultures	 in	
Matrigel	and	dissociated	to	single	cells	using	TrypLE	Express	(Thermo	Fisher),	and	pelleted.	
The	pellets	were	resuspended	in	media	with	the	addition	of	virus	and	1nM	polybrene	(Sigma	
Aldrich)	and	centrifuged	at	300g	 for	1	hour.	 The	 samples	were	 resuspended	and	plated	 in	
culture	for	between	6	hours	and	overnight,	before	replacing	the	media.	Following	recovery	
and	 expansion,	 eGFP	 positive	 cells	 were	 sorted	 by	 flow	 cytometry	 and	 further	 expanded	
before	use.		
Surface	CEA	expression	analysis	by	flow	cytometry	
Cell	lines	were	harvested	using	enzyme-free	Cell	Dissociation	Buffer	(Thermo	Fisher)	
and	PDOs	with	 TrypLE	 Express	 (Gibco).	 2x105	 cells	were	 stained	with	 20nM	of	 the	 human	
anti-human	CEA	antibody	CH1A1A	(Roche)	and	25ug/ml	of	the	R-Phycoerythrin	conjugated	
secondary	antibody	AffiniPure	F(ab')2	Fragment	Goat	Anti-Human	IgG,	Fcγ	Fragment	Specific	
(Stratech).	DRAQ7	(Biostatus)	staining	was	 included	for	dead	cell	exclusion.	CEA	expression	
was	 analysed	 on	 a	 Sony	 SH800	 flow	 cytometer.	 Gate	 boundaries	 were	 set	 at	 the	 trough	
between	 high	 and	 low	 CEA	 populations	 in	 PDOs	with	mixed	 CEA	 expression	 and	 identical	
gates	were	used	across	all	samples.	The	percentage	of	CEAhi	and	CEAlo	populations	and	mean	
fluorescence	intensities	(MFI)	were	calculated	for	each	PDO.		
CEA	expression	analysis	in	Human	Protein	Atlas	samples		
	 Microscopic	 images	 of	 11	 CRC	 samples	 stained	 by	 the	 Human	 Protein	 Atlas	
(www.proteinatlas.org)	 with	 the	 rabbit	 polyclonal	 antibody	 HPA019758	 (Sigma	 Aldrich)	
which	has	been	 validated	against	RNA	expression	data,	 immunofluorescence	 staining	with	
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an	 independent	 antibody	 and	 by	 Western	 blot	 were	 downloaded	 and	 assessed	 for	
expression	heterogeneity	by	two	pathologists	(K.	von	Loga	and	B.	Challoner).		
CD8	T	cells	expansion	from	Peripheral	Blood	Mononuclear	Cells		
	 Peripheral	 Blood	 Mononuclear	 Cells	 (PBMCs)	 were	 isolated	 from	 buffy	 coats	 with	
Ficoll-Paque	 according	 to	 the	 manufacturer’s	 protocol	 (GE	 Healthcare).	 CD8	 T	 cells	 were	
isolated	from	PBMCs	with	Human	CD8	Dynabeads	FlowComp	(Thermo	Fisher).	The	purity	of	
CD8	 T	 cells	 was	 assessed	 by	 flow	 cytometry	 (Alexa	 Fluor	 488	 anti-human	 CD8,	 Sony	
Biotechnology)	 and	 only	 populations	 with	 at	 least	 90%	 CD8	 positive	 cells	 were	 used	 for	
expansion	 with	 the	 CD3/CD28	 Dynabeads	Human	 T-Activator	 kit	 (Thermo	 Fisher)	 in	 RPMI	
1640	supplemented	with	10%	FBS	(Biosera),	1X	Glutamax,	100units	penicillin/streptomycin	
and	30	U/mL	IL-2	(Sigma	Aldrich)	following	the	manufacturer’s	protocol.	
Co-culture	of	PDOs	and	CD8	T	cells	
PDOs	 were	 harvested	 with	 TrypLE	 Express	 and	 neutralised	 with	 DMEM/F12	 Ham	
medium	 (Sigma	Aldrich)	with	 10%	 FBS.	 Cells	were	 filtered	 through	 a	 70um	 filter,	 counted	
and	re-suspended	in	phenol-red	free	RPMI	medium	(Thermo	Fisher)	supplemented	with	10%	
FBS	(Biosera),	1XGlutamax	and	100units	penicillin-streptomycin.	On	day	0,	5000	tumor	cells	
per	well	of	a	96	well-plate	(Corning	Special	Optics	Microplate)	were	plated.	CD8	T	cells	were	
added	on	day	1	at	the	indicated	effector	to	target	(E:T)	ratios	with	20nM	of	cibisatamab	or	
20nM	 of	 the	 untargeted	 negative	 control	 antibody	 DP47-TCB	 (both	 provided	 by	 Roche).	
Tumor	 cells	 without	 CD8	 T	 cells	 and	without	 antibody	were	 also	 included	 as	 controls.	 All	
conditions	were	plated	in	triplicates	and	at	least	3	different	healthy	donors	were	tested	on	
each	of	the	8	PDOs.	
Cancer	cell	growth	assessment	by	immunofluorescence	microscopy		
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The	GFP	 confluence	was	 quantified	 every	 48h-72h	 over	 a	 10-day	 period	 using	 the	
GFP	 confluence	 application	 on	 the	 Celigo	 Imaging	 Cytometer	 (Nexcelom	 Bioscience).	 GFP	
confluence	 analysis	 was	 able	 to	 track	 the	 growth	 of	 GFP	 positive	 PDO	 cells	 over	multiple	
timepoints	without	 erroneously	 counting	 the	 T	 cells	 in	 the	 co-culture.	 Confluence	 analysis	
was	furthermore	superior	to	the	counting	of	cell	nuclei	which	generated	inaccurate	results	in	
areas	of	high	cancer	cell	density	such	as	the	PDO	centre.	The	main	advantage	of	confluence	
analysis	 over	measuring	 spheroid	 diameters	 is	 the	 ability	 to	 track	 even	 the	 the	 growth	 of	
PDOs	showing	highly	variable	shapes.	Growth	curves	were	generated	with	CD8	T	cells	from	
three	different	healthy	blood	donors.	The	percentage	growth	reduction	was	calculated	from	
readings	taken	between	days	7	to	9,	before	PDOs	showed	growth	retardation,	likely	due	to	
exhaustion	of	the	growth	media.	 In	order	to	calculate	the	percentage	of	growth	reduction,	
confluence	at	day	1	was	subtracted	and	the	confluence	in	wells	treated	with	the	DP47-TCB	
control	antibody	at	the	endpoint	was	set	to	100%.		
Flow	sorting	of	CEAhi	and	CEAlo	cells	
PDOs	 cells	 were	 harvested	 with	 TrypLE	 Express,	 filtered	 through	 a	 70um	 filter	 to	
obtain	a	single	cell	solution	and	2x106	cells	were	stained	with	DAPI	for	dead	cell	exclusion,	
20nM	 of	 the	 CH1A1A	 antibody	 (Roche)	 and	 25ug/ml	 of	 the	 R-Phycoerythrin	 conjugated	
secondary	antibody	(Stratech)	and	sorted	in	CEAhi	and	CEAlo	cells	in	an	ARIAIII	cytometer	(BD	
Biosciences)	in	the	FACS	core	facility	at	the	Institute	of	Cancer	Research.	Cells	were	collected	
in	 cold	 DMEM	 supplemented	 with	 10%	 FBS	 and	 pellets	 were	 frozen	 at	 -80oC	 after	
centrifugation	 for	 RNA-sequencing.	 CEAhi	 and	 CEAlo	 cells	 sorted	 from	 CRC-06	 and	 CRC-08	
were	 also	 grown	 for	 1	 month	 in	 DMEM/F12	 Ham	 medium	 with	 20%	 FBS,	
penicillin/streptomycin	and	2%	Matrigel.		
Gene	expression	analysis	
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Total	 RNA	 was	 extracted	 from	 frozen	 pellets	 of	 flow	 sorted	 of	 CEAhi	 and	 CEAlo	
populations	 from	CRC-03,	 CRC-06	 and	CRC-08	using	RNAeasy	Plus	 (Qiagen)	 and	quantified	
with	 Qubit	 RNA	 High	 Sensitivity	 assay	 (Thermo	 Fisher).	 RNA	 sequencing	 libraries	 were	
prepared	using	the	QuantSeq	3'-mRNA-Seq	Library	Prep	Kit	FWD	for	Illumina	(Lexogen)	using	
the	manufacturer’s	protocol.	A	minimum	of	5	ng	input	RNA	was	used	from	each	sample	and	
qPCR	was	 performed	 on	 all	 samples	 before	 PCR	 amplification	 of	 the	 library	 to	 determine	
optimal	 cycle	number	 following	 the	manufacturer’s	 recommendations.	 Final	 libraries	were	
quantified	 in	 duplicate	 using	 Qubit-HS	 and	 Bioanalyzer	 High	 Sensitivity	 (Agilent)	 before	
pooling.	Libraries	were	sequenced	with	100	single	read	cycles	on	an	 Illumina	HiSeq2500	 in	
rapid	mode.	Alignment	and	gene	counting	were	performed	on	the	Lexogen	QuantSeq	data	
analysis	 pipeline	 on	 the	 Bluebee	 cloud.	 Annotation	 data	 on	 the	 GRCh38.p12	 genome	
assembly	was	exported	from	Ensembl	with	Biomart.	The	ID’s	of	protein	coding	genes	were	
identified	using	the	gtf	file	filtered	on	the	‘gene_biotype’	field.	The	Quantseq	raw	count	data	
were	then	filtered	for	this	gene	set	and	the	Ensembl	ID’s	converted	to	gene	symbol	using	the	
Homo.sapiens	 Bioconductor	 package.	 Lowly	 expressed	 genes	 containing	 fewer	 than	 10	
counts	 were	 removed	 from	 the	 dataset.	 The	 count	 data	 were	 then	 normalised	 using	 the	
estimateSizeFactors	and	counts	functions	from	the	DESeq2	Bioconductor	package(16).	
WNT/β-catenin	pathway	inhibition	assay	
105	PDO	cells/well	were	 seeded	 in	12	well	plates	and	allowed	 to	attach	overnight.	
Media	 were	 changed	 and	 cells	 were	 treated	 with	 DMSO	 control	 or	 with	 10uM	 tankyrase	
inhibitor	 (Compound	 21,	 kindly	 provided	 by	 Prof	 Lord)(17)	 or	 10uM	 porcupine	 inhibitor	
(LGK-974,	 SelleckChem)	 for	 3	 days.	 Cells	were	 harvested	 using	 TrypLE	 Express,	 stained	 for	
CEA	 with	 the	 CH1A1A	 primary	 antibody	 and	 the	 R-Phycoerythrin	 conjugated	 secondary	
antibody	and	analyzed	by	FACS	as	described	above.	
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Statistical	analyses	
Pearson	 correlation	 analysis	 and	 the	 paired	 t-tests	 were	 performed	 with	 the	
GraphPad	 Prism	 software.	 All	 p	 values	 are	 two	 tailed.	 Gene	 set	 enrichment	 analysis	 was	
performed	 with	 the	 GSEA	 software	 V3.0	 using	 5000	 gene	 set	 permutations	 and	 the	
Hallmarks	V6.2	gene	set	collection(18).		 	
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Results	
Generation	of	patient	derived	organoids	from	colorectal	cancers	
	 CRC	PDOs	were	established	as	3D	cultures	 in	Matrigel	 a)	directly	 from	core	biopsies	
from	three	chemotherapy	resistant	metastatic	CRCs	(CRC-01,	CRC-02,	CRC-06),	b)	from	small	
core	biopsies	of	four	chemotherapy	resistant	metastatic	CRCs	which	were	first	expanded	as	
xenografts	 in	 immunodeficient	 mice	 (CRC-03,	 CRC-04,	 CRC-05,	 CRC-07)	 and	 c)	 from	 an	
endoscopic	 biopsy	 taken	 from	 a	 treatment	 naive	 primary	 CRC	 (CRC-08).	 Each	 PDO	 was	
continuously	 grown	 for	 at	 least	 2	months	 in	Matrigel	 to	 test	 for	 long	 term	 viability.	 They	
were	 labelled	 with	 a	 lentivirus	 encoding	 a	 histone	 tagged	 nuclear	 enhanced	 green	
fluorescent	protein	 (eGFP)	and	were	subsequently	 transferred	 into	culture	conditions	with	
2%	Matrigel	dissolved	 in	growth	medium.	Matrigel	does	not	 form	a	solid	culture	matrix	at	
this	 dilution	 and	 allows	 PDOs	 to	 attach	 to	 the	 bottom	 of	 the	 plastic	 plate.	 These	 culture	
conditions	facilitate	interaction	with	T	cells	and	allow	monitoring	of	PDO	growth	with	wide	
field	fluorescence	light	microscopy.		
CEA	expression	heterogeneity	in	patient	derived	CRC	organoids	
	 PDOs	were	 dissociated	 into	 a	 single	 cell	 suspension	 and	CEA	 cell	 surface	 expression	
was	analysed	by	FACS	using	 the	CH1A1A	antibody	which	has	 identical	CEA	antigen	binding	
sites	to	the	cibisatamab	bispecific	antibody	(Figure	1A).	The	DLD-1	cell	 line	which	had	very	
low	 CEA	 surface	 expression	 and	 the	 MKN-45	 cell	 line	 which	 was	 most	 strongly	 positive	
among	 110	 previously	 tested	 cell	 lines	 were	 included	 as	 controls(11).	 Three	 of	 the	 PDOs	
showed	high	CEA	expression	(CRC-05,	CRC-01	and	CRC-07)	with	MFI	values	exceeding	those	
of	 the	 MKN-45	 positive	 control	 (Figure	 1B).	 A	 small	 fraction	 of	 cells	 (2.5%-10.2%	 of	 the	
whole	population)	with	low	CEA	expression	were	also	detected	in	each	of	these	PDOs.	CEA	
expression	 was	 predominantly	 negative	 in	 one	 PDO	 (CRC-06)	 but	 this	 also	 showed	 CEA	
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expression	 heterogeneity	 based	 on	 the	 presence	 of	 a	 subpopulation	 with	 high	 CEA	
expression	 (33.1%	 of	 the	whole	 population).	 Similar	 heterogeneity	 of	 CEA	 expression	was	
not	observed	in	the	DLD-1	and	MKN-45	cell	lines.	
	 The	most	striking	CEA	expression	heterogeneity	was	detected	in	4	PDOs	(CRC-02,	CRC-
03,	CRC-04	and	CRC-08)	which	each	contained	large	subpopulations	of	CEAhi	and	CEAlo	cells.	
The	MFI	of	the	CEAhi	subpopulations	were	similar	to	MKN-45	in	two	PDOs	(CRC-03,	CRC-04)	
and	moderately	lower	in	two	others	(CRC-02,	CRC-08).	A	proportion	of	the	CEAlo	cells	in	each	
of	these	four	PDOs	showed	CEA	expression	levels	which	were	as	low	as	in	the	DLD-1	cell	line,	
demonstrating	heterogeneity	across	a	broad	range	of	CEA	expression	levels.		
	 The	heterogeneous	CEA	expression	profiles	of	 these	PDOs	 is	 reminiscent	of	 the	CEA	
expression	heterogeneity	which	has	been	described	 in	CRC	samples	 from	patients(19).	We	
furthermore	 evaluated	 CRC	 tissue	 samples	 that	 had	 been	 stained	 with	 a	 validated	 CEA	
antibody	 by	 the	 Human	 Protein	 Atlas(20)	 and	 this	 also	 revealed	 CEA	 expression	
heterogeneity	 in	 6/11	 samples	 (54%;	 Figure	 1C).	 Importantly,	 similar	 expression	
heterogeneity	 to	 that	 observed	 in	 PDO	 samples	was	 not	 present	within	 DLD1	 or	MKN-45	
cells	and	bimodal	expression	profiles	have,	to	our	knowledge,	not	previously	been	described	
in	 CRC	 cell	 lines.	 This	 supports	 the	 notion	 that	 PDOs	 better	 represent	 the	 molecular	
heterogeneity	of	colorectal	cancers	than	established	cell	lines.		
Cibisatamab	sensitivity	of	PDOs	in	an	allogeneic	T	cell	co-culture	assay	
	 In	order	to	assess	the	sensitivity	of	PDOs	to	cibisatamab	immunotherapy,	CD8	T	cells	
were	isolated	from	allogeneic	healthy	donor	peripheral	blood	mononuclear	cells	(PBMCs)	by	
magnetic	bead	 sorting	and	expanded	 in	 vitro	with	 IL2	and	CD3/CD28	beads	 for	7-14	days.	
GFP-tagged	 CRC	 PDO	 cells	 were	 then	 seeded	 in	 96	 well	 plates,	 T	 cells	 were	 added	 the	
following	day	(Figure	2A)	and	the	co-cultures	were	imaged	every	2-3	days	on	an	automated	
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96	well	plate	fluorescence	microscope	(Figure	2B).	Effector	to	target	(E:T)	ratios	of	2:1	and	
5:1	were	tested	and	an	E:T	of	2:1	was	chosen	 for	subsequent	experiments	as	 it	effectively	
suppressed	growth	of	the	CEAhi	PDO	CRC-01	and	showed	no	activity	 in	the	presence	of	the	
untargeted	TCB	antibody	(DP47-TCB)	which	was	used	as	a	negative	control	(Figure	2C).	Co-
culture	with	CD8	T	cells	without	any	antibody	was	included	as	a	further	control	to	enable	the	
identification	of	alloreactive	donor	T	cells.	Co-cultures	in	which	T	cells	showed	alloreactivity	
(observed	in	less	than	one	in	ten	experiments)	were	excluded	from	the	analysis	and	assays	
were	 repeated	 until	 each	 PDO	 line	 was	 tested	 with	 CD8	 T	 cells	 from	 3	 independent	
allogeneic	donors.	
All	 three	 CEAhi	 PDOs	 were	 highly	 sensitive	 to	 treatment	 with	 CD8	 T	 cells	 and	
cibisatamab	 whereas	 the	 CEAlo	 PDO	 CRC-06	 showed	 resistance	 under	 these	 experimental	
conditions,	 as	 anticipated	 (Figure	 3A).	 Compared	 to	 conventional	 T	 cell	 killing	 assays	with	
cibisatamab	which	showed	fractional	killing	of	~40-50%	of	CEAhi	cancer	cell	lines	after	24-48	
hours(11),	 our	 assay	 assesses	 the	 impact	 over	 a	 period	 of	 7-10	 days	 and	 this	 showed	 89-
100%	growth	inhibition	 in	CEAhi	PDOs.	This	confirms	the	high	efficacy	of	cibisatamab	to	re-
direct	T	cells	to	antigen	positive	cells	in	this	assay.	
We	next	tested	the	four	PDOs	with	mixed	CEA	expression.	Each	of	these	continued	
to	 proliferate	 despite	 treatment	 with	 cibisatamab	 and	 T	 cells,	 with	 only	 a	 moderate	
reduction	of	the	cancer	cell	growth	rate	compared	to	controls	(Figure	3A	and	B).	Thus,	PDOs	
with	 mixed	 CEA	 expression	 only	 showed	 a	 partial	 response	 to	 this	 CEA	 targeting	
immunotherapy.	Correlation	analysis	of	the	achieved	growth	reduction	with	the	fraction	of	
CEAhi	cancer	cells	in	each	PDO	showed	a	strong	and	significant	correlation	(r=0.9152,	95%	CI:	
0.593	 to	0.9848;	p=0.0014;	Figure	 3C).	 This	 substantiates	 that	only	 the	CEAhi	population	 is	
sensitive	whereas	CEAlo	cells	continue	to	grow	and	promote	resistance.		
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Taken	together,	CEA	expression	was	 frequently	heterogeneous,	showing	a	bimodal	
pattern	 in	 50%	 of	 PDOs	 which	 has	 not	 been	 observed	 in	 cancer	 cell	 lines,	 and	 this	
phenomenon	was	associated	with	poor	susceptibility	to	cibisatamab	treatment.		
CEA	expression	plasticity	in	CRC	PDOs	
	 We	 next	 assessed	 if	 the	 CEAhi	 and	 CEAlo	 populations	 in	 PDOs	 were	 stable	
subpopulations	or	if	CEA	expression	would	change	over	time.	CEAhi	and	CEAlo	cells	were	FACS	
sorted	 from	CRC-08	 and	CRC-06.	 Cells	with	 intermediate	 expression	 levels	were	 discarded	
during	sorting	to	assure	that	only	cells	with	very	low	and	high	CEA	expression	were	included	
(Figure	 4A).	 CEAhi	 and	 CEAlo	 populations	were	 then	 re-expanded	 for	 1	month	 before	 CEA	
expression	profiling	and	killing	assays	were	repeated.		
The	 sorted	 CEAlo	 cells	 had	 each	 re-established	 CEAhi	 subpopulations	 which	 were	
between	47.9%	and	54.1%	of	 the	size	of	 the	CEAhi	population	 in	 the	parental	PDOs	 (Figure	
4A).	Sorted	CEAhi	cells	also	re-established	CEAlo	cell	populations	but	with	noticeable	different	
conversion	 rates	 in	 the	 two	PDOs.	 CEAhi	 cells	 from	CRC-08	had	 re-generated	58.1%	of	 the	
CEAlo	population	size	present	 in	 the	parental	cells	whereas	 those	 from	PDO	CRC-06,	which	
harbored	a	much	larger	proportion	of	CEAlo	cells	in	the	parental	population	than	CRC-08,	had	
re-generated	a	CEAlo	population	that	was	98.6%	of	the	size	of	the	parental	CEAlo	population.	
This	demonstrates	a	high	level	of	plasticity	of	CEA	expression	which	rapidly	re-establishes	a	
heterogeneous	population.		
	 We	next	re-analysed	the	sensitivity	to	cibisatamab	and	CD8	T	cell	 treatment	 in	the	
cells	 that	 had	 been	 re-expanded	 from	 sorted	 CEAhi	 and	 CEAlo	 cells.	 Similar	 to	 the	 results	
obtained	in	parental	PDOs	with	mixed	CEA	expression,	treatment	with	cibisatamab	had	low	
efficacy	(Figure	4B),	further	corroborating	that	CEAlo	cells	confer	resistance.	This	experiment	
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shows	 that	 CEA	 expression	 is	 highly	 plastic	 in	 many	 PDOs	 which	 promotes	 population	
heterogeneity	and	cibisatamab	resistance.		
Identification	of	pathways	regulating	CEA	expression		
	 We	 flow	 sorted	 CEAhi	 and	 CEAlo	 cells	 from	 3	 PDOs	 and	 performed	 RNA	 expression	
analysis	 to	 investigate	 the	 mechanisms	 that	 regulate	 CEA	 expression	 and	 generate	
heterogeneity.	 The	 median	 expression	 of	 CEACAM5	 mRNA,	 which	 encodes	 for	 the	 CEA	
protein,	was	22.8	times	higher	in	the	sorted	CEAhi	cells	compared	to	the	CEAlo	cells	(p=0.018;	
paired	t-test;	Figure	5A),	demonstrating	that	CEA	surface	expression	heterogeneity	in	these	
PDOs	 is	 regulated	 at	 the	 gene	 expression	 level.	 We	 next	 applied	 gene	 set	 enrichment	
analysis	(GSEA)(18)	to	identify	potential	molecular	pathways	which	associate	with	CEA	gene	
expression	 levels.	 Oxidative	 phosphorylation	 and	WNT/β-catenin	 signalling	 were	 the	 only	
significantly	 enriched	 signatures	 following	 multiple	 testing	 correction	 and	 both	 were	
upregulated	in	the	CEAlo	populations	(Figure	5B	and	C).		
	 Our	 aim	was	 to	 identify	 regulatory	 and	potentially	 actionable	pathways	 that	 control	
CEA	expression	and	we	hence	focused	subsequent	analyses	on	the	WNT/β-catenin	signalling	
pathway.	 This	 pathway	 is	 genetically	 activated	 in	 the	 majority	 of	 CRCs,	 most	 frequently	
through	mutations	 and	 loss	 of	 heterozygosity	 of	 the	APC	 tumor	 suppressor	 gene	 and	 less	
commonly	through	mutations	of	other	regulators	of	WNT	signalling	such	as	RNF43	or	 in	β-
catenin/CTNNB1	itself(21),(22).	Seven	of	the	PDO	samples	harbored	truncating	mutations	in	
the	 APC	 gene	 which	 result	 in	 gene	 products	 lacking	 six	 or	 seven	 of	 the	 seven	 β-catenin	
binding	 domains	 in	 the	 APC	 gene	 (Figure	 5D).	 Two	 independent	 APC	 mutations	 were	
identified	in	each	of	two	PDOs	(CRC-01,	CRC-02).	All	three	PDOs	in	which	GSEA	analysis	had	
shown	 different	 WNT/β-catenin	 signatures	 activity	 in	 FACS	 sorted	 CEAhi	 and	 CEAlo	
subpopulations	harbored	APC	mutations.	This	demonstrated	that	the	WNT	pathway	remains	
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regulated	in	these	PDOs	despite	the	presence	of	APC	mutations,	a	phenomenon	previously	
observed	 in	 CRC	model	 systems	 and	patient	 tumors(23),(24),(25).	Moreover,	 there	was	no	
association	between	the	number	of	β-catenin	binding	domains	that	were	inactivated	by	APC	
mutations	and	the	fraction	of	CEAlo	and	CEAhi	cells	in	these	eight	PDOs.		
	 High	WNT/β-catenin	pathway	activity	and	absence	of	CEA	expression	are	features	of	
the	 intestinal	 crypt	 bottom	 where	 intestinal	 stem	 cells	 reside(26),(27).	 Moreover,	 high	
WNT/β-catenin	 pathway	 activity	 is	 also	 a	 characteristic	 of	 colon	 cancer	 stem	 cells(28).	
However,	 the	 stem	 cell	 markers	 LGR5,	 CD133	 or	 CD44	 were	 not	 upregulated	 in	 CEAlo	
compared	to	CEAhi	cells	 (Figure	5E),	 suggesting	that	CEAlo	cells	do	not	represent	a	classical	
CRC	stem	cell	population(29).		
WNT/β-catenin	pathway	inhibition	increases	CEA	expression	
	 We	 finally	 investigated	 if	 pharmacological	 inhibition	 of	 the	WNT/β-catenin	 pathway	
enhances	 CEA	 expression	 as	 predicted	 by	 these	 data.	 Three	 PDO	 lines	 with	 mixed	 CEA	
expression	were	 treated	with	 two	 different	 inhibitors	 of	WNT	 signalling:	 a)	 the	 porcupine	
inhibitor	LGK-974	which	prevents	WNT	ligand	secretion	and	hence	autocrine	and	paracrine	
WNT-receptor	 activation	 and	 b)	 the	 tankyrase	 inhibitor	 compound	 21	 which	 inhibits	 the	
downstream	WNT/β-catenin	pathway	by	stabilizing	the	β-catenin	destruction	complex	 (17)	
(30).	 Both	 compounds	 increased	 CEA	 expression	 and	 the	 CEAhi	 subpopulation	 in	 all	 three	
PDOs	 (Figure	 5F).	 The	 tankyrase	 inhibitor	 consistently	 led	 to	 a	 stronger	 increase	 of	 CEA	
expression	than	porcupine	inhibitor	treatment,	perhaps	suggesting	a	limited	contribution	of	
auto-	or	paracrine	WNT	ligands	to	pathway	regulation	in	these	cells.		These	results	confirmed	
a	role	of	WNT/β-catenin	signalling	as	a	regulator	of	CEA	expression	in	CRC	PDOs.		
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Discussion	
This	 analysis	 of	 cibisatamab	 immunotherapy	 in	 a	 co-culture	model	 of	 allogeneic	 T	
cells	and	PDOs,	established	mainly	from	metastatic	chemotherapy	resistant	CRCs,	confirmed	
high	 cell	 surface	 CEA	 expression	 as	 a	 key	 determinant	 of	 treatment	 sensitivity	 in	 vitro.	
Importantly,	 in	 contrast	 to	 cell	 lines,	 we	 found	 that	 CEA	 expression	 is	 frequently	
heterogeneous	within	PDO	populations,	resulting	 in	bimodal	CEA	expression	patterns	 in	 its	
most	extreme	form.	We	furthermore	demonstrated	high	phenotypic	plasticity	that	enables	
CRC	 cells	 to	 switch	 between	 high	 and	 low	 CEA	 expression.	 These	 results	 are	 likely	 highly	
relevant	 for	 CEA	 targeting	 immunotherapies	 as	 all	 4/8	 PDOs	 with	 mixed	 CEA	 expression	
profiles	were	at	least	partially	resistant	to	cibisatamab	treatment	in	vitro.		
The	observation	that	FACS	sorted	CEAhi	cells	from	the	predominantly	CEAlo	PDO	CRC-
06	more	rapidly	converted	back	to	the	CEAlo	state	than	those	from	the	CEAmixed	PDO	CRC-08	
furthermore	 suggest	 that	 differences	 in	 the	 transition	 rate	 from	high	 to	 low	CEA	 and	 vice	
versa	may	determine	 the	abundance	of	CEAhi	and	CEAlo	 cells	at	 the	 long	 term	equilibrium.	
Moreover,	 gene	 expression	 profiles	 of	 CEAhi	 and	 CEAlo	 cells	 from	 individual	 PDOs	
demonstrated	that	cell	 surface	expression	of	CEA	 is	 regulated	at	 the	gene	expression	 level	
and	 negatively	 correlates	 with	 WNT/β-catenin	 pathway	 activity.	 CEA	 expression	 is	 tightly	
regulated	 in	 healthy	 colonic	 crypts	 where	 expression	 is	 absent	 at	 the	 crypt	 bottom	 that	
harbors	intestinal	stem	cells	and	gradually	increases	in	epithelial	cells	as	they	become	more	
differentiated	 towards	 the	 top	 of	 the	 crypt.	 The	 activity	 of	 WNT/β-catenin	 signalling	
physiologically	decreases	along	the	same	axis,	from	the	highest	levels	at	the	crypt	bottom	to	
low	signalling	activity	at	the	top	of	the	crypt.	Together	with	our	results	that	demonstrate	a	
negative	 correlation	 between	 CEA	 expression	 and	 a	 WNT/β-catenin	 activity	 signature	 in	
PDOs,	 this	 suggests	 that	 the	 regulation	 of	 CEA	 expression	 heterogeneity	 in	 PDOs	 and	 in	
healthy	colon	epithelial	cells	is	similar.		
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We	found	no	correlation	between	the	degree	of	APC	protein	truncation	by	distinct	
mutations,	 which	 is	 likely	 to	 lead	 to	 different	 levels	 of	 β-catenin	 signalling	 pathway	
activation(25),	with	CEA	expression	levels	or	CEA	heterogeneity.	In	addition,	we	showed	that	
β-catenin	 signalling	 remains	 regulated	 in	 PDOs	 despite	 genetic	 activation	 through	 APC	
mutations.	 Preservation	 of	WNT/β-catenin	 pathway	 regulation	 and	 heterogeneity	 despite	
genetic	 activation	 of	 the	 pathway	 have	 recently	 been	 shown	 in	 CRC	 cell	 lines	 and	 animal	
models	 and	 this	 has	 been	 attributed	 to	 a	 several	 cell	 intrinsic,	 autocrine	 and	 also	 stromal	
factors	 that	 influence	 multiple	 pathways	 converging	 on	 b-catenin(23),(24),(25).	 Similar	
mechanisms	may	explain	heterogeneity	in	these	PDO	models.	
The	upregulation	of	a	signature	of	oxidative	phosphorylation	in	CEAlo	cells	highlights	
further	similarities	to	intestinal	stem	cells	at	the	crypt	bottom	which	are	more	dependent	on	
oxidative	 phosphorylation	 than	 their	more	 differentiated	 progeny	 towards	 the	 top	 of	 the	
crypt(31).	Despite	the	gene	expression	similarities	between	CEOlo	cells	in	PDOs	and	the	crypt	
bottom	where	stem	cells	reside,	specific	genes	which	have	frequently	been	associated	with	
stemness	in	CRC	were	not	upregulated	in	the	CEOlo	cells	from	our	PDOs.	This	may	indicate	a	
dissociation	 of	 the	 mechanisms	 that	 regulate	 differentiation	 processes	 including	 CEA	
expression	 and	 stemness	 in	 PDOs	 from	 advanced	 and	 drug	 resistant	 tumours	 but	 this	
requires	further	investigation.		
The	 critical	 role	of	 CEA	expression	heterogeneity	 and	plasticity	 as	determinants	of	
treatment	 resistance	 in	 our	 in	 vitro	 models	 may	 be	 relevant	 for	 the	 characterization	 of	
predictive	biomarkers	for	CEA-targeting	immunotherapies	in	CRC	where	heterogeneous	CEA	
expression	has	been	described.	Moreover,	finding	strategies	to	increase	CEA	expression	may	
increase	the	clinical	responses	of	cibisatamab.	
PDOs	 harboring	 predominantly	 CEAhi	 cells	 were	 highly	 sensitive	 to	 cibisatamab	
treatment	 in	vitro	but	the	 low	 level	of	expression	plasticity	we	observed	may	nevertheless	
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enable	gradual	 loss	of	the	target	antigen	during	prolonged	treatment.	The	plasticity	of	CEA	
expression	which	re-establishes	a	CEAhi	population	after	FACS	sorting	of	CEAlo	cells	suggests	
that	re-treatment	with	cibisatamab	after	a	prolonged	treatment	break	may	 lead	to	further	
responses.	 Phenotypic	 plasticity	 may	 furthermore	 be	 amenable	 to	 combination	 therapies	
which	 either	 increase	 CEA	 expression	 in	 the	 CEAlo	 population	 or	 which	 co-target	
vulnerabilities	of	the	CEAlo	subpopulations	while	also	administering	cibisatamab.	Our	results	
provided	 proof	 of	 principle	 that	 CEA	 expression	 can	 be	 pharmacologically	 perturbed	 and	
indicate	WNT	pathway	inhibitors,	which	are	in	clinical	development,	as	a	potential	strategy	
to	 boost	 CEA	 expression	 and	 increase	 therapeutic	 benefit	 from	 bispecific	 CEA-targeting	
antibodies.	However,	 the	WNT	pathway	has	 an	essential	 role	 in	 the	development	 and	 the	
homeostasis	of	many	normal	tissues	in	the	human	body	.	As	a	consequence,	targeting	of	the	
WNT	pathway	has	been	challenging	in	preclinical	models	and	clinical	trials,	particularly	due	
to	 gastrointestinal	 toxicities(32).	 However,	 there	 is	 cautious	 optimism	 that	 a	 better	
understanding	of	WNT	regulation	in	malignant	cells	and	of	the	cross-talk	between	the	WNT	
and	 other	 signaling	 pathways	 in	 cancer	 may	 enable	 the	 design	 of	 new	 molecules	 with	 a	
broader	therapeutic	window	and	lower	toxicity(30).	Our	results	also	question	whether	CEAlo	
cells	may	be	susceptible	to	inhibition	of	oxidative	phosphorylation	as	an	alternative	strategy	
to	address	 this	 subpopulation.	Several	CEA	 targeting	 immunotherapies	beyond	bispecific	T	
cell	redirecting	antibodies	are	currently	in	preclinical	or	clinical	development,	 including	CEA	
vaccines	 and	 CEA	 targeting	 CAR	 T	 cells	 or	 TCR	 engineered	 T	 cells(33).	 CEA	 expression	
plasticity	 and	 heterogeneity	 are	 likely	 hindrances	 for	 each	 of	 these	 approaches.	 Together	
with	 the	 limited	 success	 that	 has	 so	 far	 achieved	 in	MSS	 CRCs	 with	 checkpoint	 inhibiting	
immunotherapies	 alone,	 strategies	 to	 enhance	 CEA	 expression	 in	 combination	 with	 CEA	
targeting	 therapies	 appear	 promising	 to	 extend	 immunotherapy	 benefit	 to	 a	 larger	
proportion	of	CRC	patients.		
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Finally,	this	study	shows	the	potential	of	PDO	and	allogeneic	T	cell	co-cultures	as	novel	tools	
to	dissect	mechanisms	of	immunotherapy	resistance	in	vitro.	This	addresses	a	major	need	in	
translational	 immunotherapy	research,	particularly	as	studies	 in	 immunocompetent	animal	
models	are	often	slow	and	expensive	and	sometimes	even	impossible	as	animal	models	are	
not	 available	 for	 all	 tumor	 types,	 or	 are	 incompatible	 with	 human-specific	 reagents,	
including	 many	 monoclonal	 antibodies.	 Allogeneic	 systems	 can	 be	 hampered	 by	
alloreactivity	where	donor	T	cells	recognize	MHC	molecules	on	target	cells	as	non-self.	This	
can	 lead	to	high	background	killing	activity	that	may	 impair	assay	sensitivity	and	specificity	
compared	to	autologous	systems.	Cancer	cells	alone	as	well	as	in	co-culture	with	T	cells	but	
without	 antibody	were	 included	 as	 controls	 in	 our	 assays.	 This	 allowed	 us	 to	 identify	 and	
exclude	 the	 small	 number	 of	 experiments	 in	 which	 alloreactivity	 impaired	 cancer	 cell	
growth.	Using	allogeneic	T	cells	in	PDO	co-culture	models	hence	represent	a	valid	alternative	
strategy	when	 autologous	 T	 cells	 are	 unavailable.	 These	 PDO	T	 cell	 co-culture	models	 can	
accelerate	the	discovery	of	immune-oncology	candidate	resistance	mechanisms,	biomarkers	
of	efficacy	and	define	rational	combination	therapy	strategies	for	clinical	testing.	The	ability	
of	 PDOs	 to	 represent	 intra-tumor	 heterogeneity	 to	 some	 degree,	 and	 the	 opportunity	 to	
establish	them	from	tumors	which	match	the	stage	and	the	treatment	history	of	patients	in	
which	novel	drugs	are	tested,	are	decisive	advantages	for	pre-clinical	discovery.		
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Conclusions	
CEA	 expression	 heterogeneity	 is	 common	 in	 CRC	 PDOs	 from	 therapy	 resistant	
metastatic	 CRCs	 and	 this	 confers	 cibisatamab	 resistance	 in	 vitro.	Whether	 CEA	 expression	
heterogeneity	 is	 associated	 with	 cibisatamab	 resistance	 should	 be	 investigated	 in	 clinical	
trial	 samples.	 CEA	 expression	 can	 be	 pharmacologically	 enhanced	 through	WNT/β-catenin	
pathway	inhibition,	suggesting	opportunities	for	combination	therapies	that	should	increase		
cibisatamab		efficacy	in	the	clinic.		
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List	of	abbreviations:	
CAR:	Chimeric	Antigen	Receptor		
CEA:	Carcino	Embryonic	Antigen	
CEA-TCB:	Carcino	Embryonic	Antigen-T	Cell	Bispecific		
CRC:	Colorectal	cancer	
E:T:	Effector	to	Target	
FACS:	Fluorescence-Activated	Cell	Scanning	
eGFP:	enhance	Green	Fluorescent	Protein	
GSEA:	Gene	Set	Enrichment	Analysis	
IL2:	Interleukin	2	
MFI:	Mean	Fluorescence	Intensity	
MSI:	Microsatellite	instable	
MSS:	Microsatellite	stable	
PBMCs:	Peripheral	Blood	Mononuclear	Cells	
PD-L1:	Programmed	Death	Ligand	1	
PDO:	Patient	Derived	Organoid	
TCR:	T	Cell	Receptor	 	
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Figure	Legends:	
Figure	1.	A:	FACS	analysis	of	CEA	cell	surface	expression	for	DLD-1	and	MKN-45	cell	lines	and	
8	 PDOs.	 Gates	 were	 adjusted	 on	 the	 trough	 of	 CRC-03	 and	 identical	 gates	 were	 used	 to	
quantify	 the	percentage	of	CEAhi/lo	cells	 in	all	 lines.	B:	Summary	of	CEA	hi/lo	percentages	and	
measured	 mean	 fluorescent	 intensities	 (MFIs)	 of	 the	 data	 in	 panel	 A.	C:	CEA	 protein	
expression	 heterogeneity	 identified	 in	 6/11	 CRC	 samples	 stained	 with	 the	 anti-
CEA/CEACAM5	 antibody	 HPA019758.	 Examples	 of	 CEA	 heterogeneity	 are	 highlighted	 by	
white	 (low	 CEA)	 and	 black	 (high	 CEA)	 arrows.	 Numbers	 indicate	 the	 Human	 Protein	 Atlas	
patient	 IDs.	 (images:	 courtesy	 of	 the	 Human	 Protein	 Atlas	v18.proteinatlas.org;	
link:	https://www.proteinatlas.org/ENSG00000105388	
CEACAM5/pathology/tissue/colorectal+cancer#img)	
Figure	 2.	A:	Diagram	 of	 the	 PDO	 and	 allogeneic	 CD8	 T	 cell	 co-culture	 model.	B:		Example	
showing	 GFP	 fluorescence	 imaging	 of	 a	 co-culture	 model	 treated	 with	 the	 bispecific	
untargeted	 control	 antibody	 and	 cibisatamab	 over	 a	 period	 of	 8	 days.	C:	Growth	 curves	
generated	with	different	effector	to	target	(E:T)	ratios	in	the	CEAhi	PDO	CRC-01	during	assay	
development.	
Figure	3	A:	Growth	curves	for	all	eight	PDO	lines	treated	with	cibisatamab	or	controls	during	
10	 days	 of	 co-culture.	 Each	 PDO	was	 cultured	with	 T	 cells	 from	 three	 different	 allogeneic	
donors	 at	 an	 E:T	 ratio	 of	 2:1	 and	 means	 are	 shown.	B:	Comparison	 	of	 the	 fraction	 of	
CEAhi		cells	in	each	PDO	with	the	growth	reduction	in	achieved	at	the	essay	endpoint	in	panel	
A.	C:		Correlation	analysis	of	growth	reduction	and	the	fraction	of	CEAhi	cells	for	all	PDOs.	A	
linear	regression	line	and	the	Pearson	correlation	coefficient	and	p	value	of	the	significance	
test	are	shown.	
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Figure	4.	A:	Baseline	CEA	expression	profile	measured	by	FACS,	gates	for	sorting	of	CEAlo	and	
CEAhi	cells	 and	 CEA	 expression	 profiles	 of	 the	 sorted	 cells	 following	 re-expansion	 for	 1	
month.	Sorting	dot-blots	also	show	GFP	positivity	of	the	PDO	lines	including	a	subpopulation	
of	 genome	 doubled	 cancer	 cells,	 that	 shows	 increased	 GFP	 signal	 due	 to	 higher	 histone	
content,	 which	 was	 repeatedly	 observed	 in	 CRC-08.	B:	Growth	 curves	 of	
sorted	CEAhi	and		CEAlo		PDO	cells	that	had	been	re-expanded	for	1	month	before	cibisatamab	
sensitivity	was	re-analysed	in	the	PDO	and	T	cell	co-culture	assay	at	an	E:T	ratio	of	2:1.	
Figure	5.	A:	CEA/CEACAM5	mRNA	expression	in	sorted	CEAhi/lo	cells.	A	paired	Student’s	t-test	
was	 applied	 to	 log2	 transformed	 gene	 expression	 data	 for	 significance	
analysis.	 	B:	Significant	 results	 of	 the	 gene	 set	 enrichment	 analysis	 of	 sorted	CEAhi	and	
CEAlo	cells	 from	CRC-03,	CRC-08	and	CRC-06.	WNT/β-catenin	and	oxidative	phosphorylation	
signatures	were	significantly	enriched	in	cells	expressing	low	CEA	levels.	C:	mRNA	expression	
heatmaps	 generated	 by	 GSEA	 showing	 expression	 levels	 of	 genes	 in	 the	 significantly	
enriched	pathways.	D:	Representation	of	 the	APC	gene	and	of	 the	specific	protein	changes	
encoded	 by	 APC	 mutations	 found	 in	 7/8	 PDOs.	E:	Expression	 of	 genes	 which	 have	 been	
described	as	CRC	stem	cell	markers	in	sorted	CEAhi/lo	cells.	F:	CEA	expression	analysis	of	PDOs	
treated	 for	4	days	with	DMSO	control	 (grey),	with	a	10uM	of	porcupine	 inhibitor	 (blue)	or	
10uM	of	a	Tankyrase	inhibitor.	
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